All In Biotech

Drug Trial Radar · NCT05712187

Phase 2b Study of ALTO-100 in MDD

A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-100 With an Open-Label Extension in Adults With Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 301 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

301

Actual

Start

Jan 10, 2023

Primary completion

Sep 5, 2024

Study completion Oct 24, 2024

Sponsor

Lead sponsor
Alto NeuroscienceIndustry
Sponsor type
Industry
First posted
Feb 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine efficacy differences between ALTO-100 and placebo, used either as monotherapy or adjunctively to an antidepressant, related to patient characteristics.

Conditions

  • Major Depressive Disorder

Interventions

  • ALTO-100Drug

    ALTO-100 tablet BID

  • PlaceboDrug

    Placebo tablet BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess efficacy of ALTO-100 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change from Day 1 to Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score.Time frame: Change assessed from Day 1 to Week 6

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Site 174

    Birmingham, Alabama

  • Site 173

    Huntsville, Alabama

  • Site 136

    Chandler, Arizona

  • Site 139

    Little Rock, Arkansas

  • Site 141

    Costa Mesa, California

  • Site 118

    Fresno, California

  • Site 181

    Imperial, California

  • Site 182

    Oceanside, California

  • Site 188

    Oceanside, California

  • Site 179

    Rancho Cucamonga, California

  • Site 116

    Sacramento, California

  • Site 185

    Centennial, Colorado

  • Site 186

    Brooksville, Florida

  • Site 204

    Jacksonville, Florida

  • Site 205

    Orlando, Florida

  • Site 212

    Tampa, Florida

  • Site 213

    Tampa, Florida

  • Site 137

    Carmel, Indiana

  • Site 151

    Baltimore, Maryland

  • Site 108

    Jackson, Mississippi

  • Site 171

    Jackson, Mississippi

  • Site 142

    Lincoln, Nebraska

  • Site 144

    Las Vegas, Nevada

  • Site 178

    Albuquerque, New Mexico

  • Site 184

    Brooklyn, New York

  • Site 180

    New York, New York

  • Site 210

    New York, New York

  • Site 175

    Westlake, Ohio

  • Site 157

    North Charleston, South Carolina

  • Site 183

    Memphis, Tennessee

  • Site 147

    Fort Worth, Texas

  • Site 120

    Houston, Texas

  • Site 172

    Houston, Texas

  • Site 121

    Draper, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.